Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3180912 | Actas Dermo-Sifiliográficas | 2011 | 11 Pages |
Abstract
There was a high frequency of rebound following suspension of efalizumab, exceeding the rate reported in pivotal trials. This is particularly noteworthy given the large proportion of patients with a good response to treatment and therefore believed to have a better prognosis. Other significant findings were the higher frequency of positive treatment response than observed in previous studies (possibly influenced by the mean treatment duration) and the high frequency of generalized inflammatory flares.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
L. Morell, J.M. Carrascosa, C. Ferrándiz, M. GarcÃa-Bustinduy, E. Fonseca, G. Carretero, E. Daudén, S.E. Marrón, J.L. López-Estebaranz, M. Ferrán, M. Sánchez-Regaña, C. Muñoz-Santos, I. Belinchón, Luis Puig,